Merck KGaA (MRK) Stock Forecast & Price Target

Compare

130 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRK Analyst Ratings

Moderate Buy

7 Buy

1 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Merck

KGaA

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

€147.43

▲(33.66%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Merck KGaA in the last 3 months. The average price target is €147.43 with a high forecast of €182.00 and a low forecast of €100.00. The average price target represents a 33.66% change from the last price of €110.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"99":"€99","120":"€120","141":"€141","162":"€162","183":"€183"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€182.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€147.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[99,120,141,162,183],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.15,112.90769230769232,118.66538461538462,124.42307692307693,130.18076923076924,135.93846153846155,141.69615384615383,147.45384615384614,153.21153846153845,158.96923076923076,164.72692307692307,170.48461538461538,176.2423076923077,{"y":182,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.15,110.24846153846154,113.34692307692308,116.44538461538463,119.54384615384616,122.6423076923077,125.74076923076923,128.83923076923077,131.93769230769232,135.03615384615387,138.1346153846154,141.23307692307694,144.33153846153846,{"y":147.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.15,106.60000000000001,106.05000000000001,105.5,104.95,104.4,103.85000000000001,103.3,102.75,102.2,101.65,101.1,100.55,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":165.243,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.018,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.559,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.252,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.274,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.359,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.741,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.579,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.301,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€182.00

Average Price Target€147.43

Lowest Price Target€100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

€125

Buy

13.33%

Upside

Upgraded

07/09/25

Merck KGaA's overall stock score is driven by its strong financial performance and fair valuation. The company's robust profitability, efficient operations, and solid balance sheet underpin its financial health. Technical analysis suggests a slightly bearish trend, but the company's valuation remains reasonable. The absence of earnings call and corporate events data means these factors did not influence the score.

Florent CespedesBernstein

Bernstein

€147

Hold

33.27%

Upside

Reiterated

08/01/25

Merck KGaA (0O14) Receives a Hold from Bernstein

Charles Pitman CFABarclays

Barclays

€160→€150

Buy

35.99%

Upside

Reiterated

07/30/25

Barclays Sticks to Its Buy Rating for Merck KGaA (0O14)

Richard VosserJ.P. Morgan

J.P. Morgan

€155

Buy

40.53%

Upside

Reiterated

07/30/25

Merck KGaA (0O14) Receives a Buy from J.P. Morgan

Peter SpenglerDZ BANK AG

DZ BANK AG

―

Buy

―

Reiterated

07/28/25

Merck KGaA (0O14) Receives a Buy from DZ BANK AG

Falko FriedrichsDeutsche Bank

Deutsche Bank

€174→€140

Buy

26.93%

Upside

Reiterated

07/24/25

James QuigleyGoldman Sachs

Goldman Sachs

€165→€158

Buy

43.25%

Upside

Reiterated

07/24/25

Goldman Sachs Reaffirms Their Buy Rating on Merck KGaA (0O14)

Dylan Van HaaftenStifel Nicolaus

Stifel Nicolaus

€153→€100

Sell

-9.34%

Downside

Downgraded

07/07/25

Merck KGaA (0O14) was downgraded to a Sell Rating at Stifel Nicolaus

Colin WhiteUBS

UBS

―

Buy

―

Reiterated

07/01/25

UBS Keeps Their Buy Rating on Merck KGaA (0O14)

David EvansKepler Capital

Kepler Capital

€182

Buy

65.00%

Upside

Reiterated

05/15/25

Kepler Capital Keeps Their Buy Rating on Merck KGaA (0O14)

Peter VerdultExane BNP Paribas

Exane BNP Paribas

€107

Sell

-2.99%

Downside

Initiated

04/16/25

BNP Paribas Exane Starts Merck KGaA (MRK:GR) (MKGAF) at UnderperformBNP Paribas Exane analyst Peter Verdult initiates coverage on Merck KGaA (MRK:GR) (OTC: MKGAF) with a Underperform rating and a price target of EUR107.00.

Thibault BoutherinMorgan Stanley

Morgan Stanley

€190→€160

Hold

45.06%

Upside

Downgraded

02/12/25

Morgan Stanley Downgrades Merck KGaA (MRK:GR) (MKGAF) to EqualweightMorgan Stanley analyst Thibault Boutherin downgraded Merck KGaA (MRK:GR) (OTC: MKGAF) from Overweight to Equalweight with a price target of EUR160.00 (from EUR190.00).

Brian BalchinJefferies

Jefferies

―

Buy

―

Reiterated

01/21/25

Jefferies Keeps Their Buy Rating on Merck KGaA (0O14)

Evan SeigermanBMO Capital

BMO Capital

€131.25

Buy

18.99%

Upside

Reiterated

10/23/24

BMO Capital Sticks to Their Buy Rating for Merck KGaA (0O14)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

€125

Buy

13.33%

Upside

Upgraded

07/09/25

Florent CespedesBernstein

Bernstein

€147

Hold

33.27%

Upside

Reiterated

08/01/25

Merck KGaA (0O14) Receives a Hold from Bernstein

Charles Pitman CFABarclays

Barclays

€160→€150

Buy

35.99%

Upside

Reiterated

07/30/25

Barclays Sticks to Its Buy Rating for Merck KGaA (0O14)

Richard VosserJ.P. Morgan

J.P. Morgan

€155

Buy

40.53%

Upside

Reiterated

07/30/25

Merck KGaA (0O14) Receives a Buy from J.P. Morgan

Peter SpenglerDZ BANK AG

DZ BANK AG

―

Buy

―

Reiterated

07/28/25

Merck KGaA (0O14) Receives a Buy from DZ BANK AG

Falko FriedrichsDeutsche Bank

Deutsche Bank

€174→€140

Buy

26.93%

Upside

Reiterated

07/24/25

James QuigleyGoldman Sachs

Goldman Sachs

€165→€158

Buy

43.25%

Upside

Reiterated

07/24/25

Goldman Sachs Reaffirms Their Buy Rating on Merck KGaA (0O14)

Dylan Van HaaftenStifel Nicolaus

Stifel Nicolaus

€153→€100

Sell

-9.34%

Downside

Downgraded

07/07/25

Merck KGaA (0O14) was downgraded to a Sell Rating at Stifel Nicolaus

Colin WhiteUBS

UBS

―

Buy

―

Reiterated

07/01/25

UBS Keeps Their Buy Rating on Merck KGaA (0O14)

David EvansKepler Capital

Kepler Capital

€182

Buy

65.00%

Upside

Reiterated

05/15/25

Kepler Capital Keeps Their Buy Rating on Merck KGaA (0O14)

Peter VerdultExane BNP Paribas

Exane BNP Paribas

€107

Sell

-2.99%

Downside

Initiated

04/16/25

Thibault BoutherinMorgan Stanley

Morgan Stanley

€190→€160

Hold

45.06%

Upside

Downgraded

02/12/25

Brian BalchinJefferies

Jefferies

―

Buy

―

Reiterated

01/21/25

Jefferies Keeps Their Buy Rating on Merck KGaA (0O14)

Evan SeigermanBMO Capital

BMO Capital

€131.25

Buy

18.99%

Upside

Reiterated

10/23/24

BMO Capital Sticks to Their Buy Rating for Merck KGaA (0O14)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck KGaA

1 Month

xxx

Success Rate

30/52 ratings generated profit

Average Return

+1.08%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +1.08% per trade.

3 Months

xxx

Success Rate

19/31 ratings generated profit

Average Return

+4.11%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.29% of your transactions generating a profit, with an average return of +4.11% per trade.

1 Year

David EvansKepler Capital

Success Rate

32/52 ratings generated profit

Average Return

+7.50%

reiterated a buy rating 3 months ago

Copying David Evans's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +7.50% per trade.

2 Years

xxx

Success Rate

19/31 ratings generated profit

Average Return

+18.88%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 61.29% of your transactions generating a profit, with an average return of +18.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRK has received 11 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. MRK average Analyst price target in the past 3 months is 147.43.

Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is €2.14 with a range of €2.10 to €2.17. The previous quarter’s EPS was €2.12. MRK beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.08% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is €5.31B with a range of €5.27B to €5.37B. The previous quarter’s sales results were €5.28B. MRK beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 47.21% of the time in the same period. In the last calendar year MRK has Outperformed its overall industry.

MRK Stock Forecast FAQ

What is DE:MRK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck KGaA’s 12-month average price target is 147.43.

What is DE:MRK’s upside potential, based on the analysts’ average price target?

Merck KGaA has 33.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Merck KGaA a Buy, Sell or Hold?

Merck KGaA has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 1 hold ratings and 1 sell ratings.

What is Merck KGaA’s share price target?

The average share price target for Merck KGaA is 147.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €182.00 ,and the lowest forecast is €100.00. The average share price target represents 33.66% Increase from the current price of €110.3.

What do analysts say about Merck KGaA?

Merck KGaA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Merck KGaA?

To buy shares of DE:MRK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Merck KGaA (MRK) Stock Forecast & Price Target

MRK Analyst Ratings

MRK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck KGaA

MRK Analyst Recommendation Trends

MRK Financial Forecast

MRK Earnings Forecast

MRK Sales Forecast

MRK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts